{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:10:37Z","timestamp":1759335037812,"version":"build-2065373602"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10072-025-08269-6","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:51:12Z","timestamp":1748883072000},"page":"5431-5435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of local and delayed cutaneous hypersensitivity reactions to anti-CGRP antibodies: implications for continuing treatment"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-6616","authenticated-orcid":false,"given":"Celia","family":"Romero del Rincon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9420-8448","authenticated-orcid":false,"given":"Paula","family":"Panos Basterra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5332-1850","authenticated-orcid":false,"given":"Patricia","family":"Heredia-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1786-7535","authenticated-orcid":false,"given":"Jos\u00e9 Mar\u00eda","family":"Serra L\u00f3pez-Matencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6120-0714","authenticated-orcid":false,"given":"Francisco","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-3406","authenticated-orcid":false,"given":"Ana Beatriz","family":"Gago-Veiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"8269_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/head.13432","volume":"59","author":"FR Taylor","year":"2019","unstructured":"Taylor FR (2019) CGRP, Amylin, immunology, and headache medicine. Headache 59:131\u2013150. https:\/\/doi.org\/10.1111\/head.13432","journal-title":"Headache"},{"key":"8269_CR2","doi-asserted-by":"publisher","unstructured":"Serra L\u00f3pez-Matencio JM, Gago-Veiga AB, G\u00f3mez M, et al (2022) Treatment of migraine with monoclonal antibodies. Expert Opin Biol Ther 22. https:\/\/doi.org\/10.1080\/14712598.2022.2072207","DOI":"10.1080\/14712598.2022.2072207"},{"issue":"2","key":"8269_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","volume":"40","author":"SD Silberstein","year":"2023","unstructured":"Silberstein SD, Reshef S, Cohen JM et al (2023) Adverse events reported with therapies targeting the cgrp pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther 40(2):445\u2013459. https:\/\/doi.org\/10.1007\/s12325-022-02346-4","journal-title":"Adv Ther"},{"issue":"10","key":"8269_CR4","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M (2020) Safety and tolerability of 3 CGRP monoclonal antibodies in practice: a retrospective cohort study. Headache 60(10):2454\u20132462. https:\/\/doi.org\/10.1111\/head.13956","journal-title":"Headache"},{"key":"8269_CR5","doi-asserted-by":"publisher","unstructured":"Jutel M, Agache I, Zemelka-Wiacek M, et al (2023) Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: An EAACI position paper. Allergy 78. https:\/\/doi.org\/10.1111\/all.15889","DOI":"10.1111\/all.15889"},{"key":"8269_CR6","doi-asserted-by":"publisher","unstructured":"M\u00fcller CSL, Bourg C, Schweitzer LF, Friesenhahn-Ochs B, Pf\u00f6hler C (2023) Injection Site Reaction to Various Insulins as Type III Allergy with Urticarial Vasculitis in a Patient with Type i Diabetes Mellitus. Am J Dermatopathol 45. https:\/\/doi.org\/10.1097\/DAD.0000000000002356","DOI":"10.1097\/DAD.0000000000002356"},{"key":"8269_CR7","doi-asserted-by":"publisher","unstructured":"Trautmann A, Seitz CS (2009) Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. Immunol Allergy Clin North Am 29. https:\/\/doi.org\/10.1016\/j.iac.2009.04.006","DOI":"10.1016\/j.iac.2009.04.006"},{"key":"8269_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/cod.14018","volume":"86","author":"B Moya","year":"2022","unstructured":"Moya B, Barranco R, Garc\u00eda-Moguel I et al (2022) First confirmed case of nonimmediate hypersensitivity to fremanezumab during chronic migraine treatment. Contact Dermatitis 86:308\u2013310. https:\/\/doi.org\/10.1111\/cod.14018","journal-title":"Contact Dermatitis"},{"key":"8269_CR9","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s40122-022-00417-6","volume":"11","author":"CH G\u00f6bel","year":"2022","unstructured":"G\u00f6bel CH, Heinze A, Karstedt S et al (2022) First report of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE or Baboon Syndrome) after erenumab application for migraine prevention. Pain Ther 11:1483\u20131491. https:\/\/doi.org\/10.1007\/s40122-022-00417-6","journal-title":"Pain Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08269-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08269-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T03:11:46Z","timestamp":1759288306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08269-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":9,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["8269"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08269-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Celia Romero del Rinc\u00f3n has received support for attending meetings from Pfizer. Patricia Heredia-Rodriguez has received honoraria from Lundbeck, Novartis, Abbvie, TEVA and Pfizer S.L.U. Francisco Vega has received honoraria from Rovi, Chiesi and GSK. Ana Beatriz Gago-Veiga has received honoraria from Lilly, Novartis, TEVA, Abbvie-Allergan, Lunbeck and Pfizer. Paula Panos Basterra and Jos\u00e9 Mar\u00eda Serra L\u00f3pez-Matencio report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"None","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients for the publication of their cases and accompanying images, in accordance with ethical guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}